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Abstract
 
Excessive proliferation of vascular smooth muscle cells
(VSMCs) contributes to vessel renarrowing after angio-
plasty. Here we investigated the transcriptional regulation
of the cyclin A gene, a key positive regulator of S phase that
is induced after angioplasty. We show that Ras-dependent
mitogenic signaling is essential for the normal stimulation
of cyclin A promoter activity and DNA synthesis in VSMCs.
Overexpression of the AP-1 transcription factor c-fos can
circumvent this requirement via interaction with the cAMP-
responsive element (CRE) in the cyclin A promoter. More-
over, c-fos overexpression in serum-starved VSMCs results
in the induction of cyclin A promoter activity in a CRE-
dependent manner, and increased binding of endogenous
c-fos protein to the cyclin A CRE precedes the onset of
DNA replication in VSMCs induced by serum in vitro and
by angioplasty in vivo. We also show that E2F function is
essential for both serum- and c-fos–dependent induction of
cyclin A expression. Taken together, these findings suggest
that c-fos and E2F are important components of the signal-
ing cascade that link Ras activity to cyclin A transcription
in VSMCs. These studies illustrate a novel link between the
transcriptional and cell cycle machinery that may be rele-
vant to the pathogenesis of vascular proliferative disorders.
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Introduction
 
A fully differentiated phenotype and low proliferative rate
 
characterize vascular smooth muscle cells (VSMCs)
 
1
 
 in adult
animals. However, in response to different forms of insult to
the vessel wall, VSMCs undergo abnormal proliferation and
migration and organize into an atherosclerotic lesion that com-
promises normal blood flow (1–5). Excessive proliferation of
VSMCs is also thought to contribute to restenosis, a complica-
tion that limits the long-term success of revascularization in
 
z
 
 25–55% of patients undergoing percutaneous transluminal
coronary angioplasty (6–8). Although previous studies using
antisense oligonucleotides and arterial gene transfer strategies
have implicated both positive and negative regulators of
VSMC growth in lesion development after angioplasty (9–27),
little is known about the transcriptional networks governing
the expression of cell cycle control genes in VSMCs.
Progression through the mammalian cell cycle is regulated
essentially by the balance between multiple cyclin-dependent
kinase (CDK)/cyclin holoenzymes and growth suppressor pro-
teins (28–33). Recent studies suggested that Ras-activated mi-
togenic signaling promotes cell proliferation via activation of
the G1 CDK/cyclin/E2F pathway (34–40), and inhibition of
cellular Ras prevents VSMC proliferation after vascular injury
in vivo (41, 42). We have shown recently that injury-induced
VSMC proliferation in rat and human arteries is associated
with a temporally and spatially coordinated induction of
CDK2 and its regulatory subunits, cyclin E and cyclin A (43).
To elucidate molecular mechanisms underlying Ras-depen-
dent induction of cell cycle control genes that may be relevant
to the pathogenesis of vascular proliferative disorders, we have
analyzed the transcriptional regulation of cyclin A gene ex-
pression in VSMCs. Our findings suggest that the interaction
of c-fos with the cAMP-responsive element (CRE) site at posi-
tion 
 
2
 
79/
 
2
 
72 in the cyclin A promoter is an important compo-
nent of the signaling cascade that links Ras activity to cyclin A
expression and VSMC proliferation. We also show that both
this CRE site and the E2F motif at 
 
2
 
37/
 
2
 
32 are essential for
the normal serum- and c-fos–dependent induction of cyclin A
promoter activity in VSMCs.
 
Methods
 
Transient transfections and luciferase assays.
 
The cloned PAC1 rat
pulmonary arterial smooth muscle cell line was used in these studies,
which has been shown to maintain through multiple subcultures many
differentiated properties of intact VSMCs and can be transfected effi-
ciently (44). Cells were seeded into 6-well dishes and maintained in
 
Address correspondence to Vicente Andrés, Ph.D., Division of Car-
diovascular Research, St. Elizabeth’s Medical Center, 736 Cambridge
Street, Boston, MA 02135. Phone: 617-562-7509; FAX: 617-562-7506;
E-mail: vicente_andres@hotmail.com
 
Received for publication 2 September 1997 and accepted in revised
form 8 January 1998.
 
1. 
 
Abbreviations used in this paper:
 
 BrdU, bromodeoxyuridine; CDK,
cyclin-dependent kinase; CMV, cytomegalovirus; CRE, cAMP-respon-
sive element; CREB, CRE-binding protein; EMSA, electrophoretic
mobility shift assay; RSV, Rous sarcoma virus; VSMC, vascular
smooth muscle cell.
 
 c-fos– and E2F-dependent Control of Cyclin A Transcription in Vascular SMCs
 
941
 
M199 medium supplemented with 20% FBS as described previously
(9). The next day, cells (
 
z
 
 60–80% confluence) were transiently
transfected with Lipofectamine reagent (GIBCO BRL, Gaithersburg,
MD) and the indicated reporter constructs and expression vectors
(1:3 DNA/Lipofectamine ratio). To determine the efficiency of trans-
fection, PAC1 cells were transfected with 1–2.5 
 
m
 
g of pHook-3
 
LacZ
 
expression vector (Invitrogen Corp., Carlsbad, CA) which ex-
presses 
 
b
 
-galactosidase driven by the cytomegalovirus (CMV) pro-
moter. 3 d after transfection, cells were fixed with 2% paraformalde-
hyde/PBS followed by colorimetric assay for 
 
b
 
-galactosidase using
5-bromo-4-chloro-3-indolyl-
 
b
 
-
 
D
 
-galactopyranoside substrate (0.5 mg/
ml; Promega Corp., Madison, WI). Microscopic examination dis-
closed lack of staining in mock-transfected cells and 6.1% of stained
cells for both 1 and 2.5 
 
m
 
g of transfected pHook-3
 
LacZ
 
 plasmid (total
number of cells scored 
 
5
 
 2,002 and 2,756, respectively).
Luciferase reporter plasmids driven by the human cyclin A pro-
moter region from 
 
2
 
924 to 
 
1
 
245 (wild-type and CRE mutant) (45,
46) were provided by J. Sobczak-Thépot (INSERM, Paris). The hu-
man cyclin A promoter regions from 
 
2
 
79 to 
 
1
 
100 (wild-type and
E2F mutant) and from 
 
2
 
54 to 
 
1
 
100 were generated by PCR and sub-
cloned into pGL2-Basic (Promega Corp.). The 
 
2
 
79/
 
1
 
100 E2F mu-
tant contained the sequence AATTCG at position 
 
2
 
37 to 
 
2
 
32, which
disrupts the E2F site that confers serum responsiveness of the human
cyclin A promoter (47). PCR-generated plasmids were verified by se-
quence analysis. p-356wt/fos luciferase reporter construct containing
the murine c-fos promoter region from 
 
2
 
356 to 
 
1
 
109 (48) and
pEMSV-c-fos expression vector containing the full-length cDNA for
rat c-fos were provided by M. Simonson (Case Western Reserve Uni-
versity, Cleveland, OH). Expression vector pCMV5-Kip1 containing
the full-length cDNA for murine p27
 
Kip1
 
 (49) was provided by J. Mas-
sagué (Memorial Sloan-Kettering Cancer Center, New York). Final
DNA concentration in experiments involving cotransfection of ex-
pression vectors was equalized by adding empty expression vector.
To correct for differences in transfection efficiency, luciferase activity
was normalized relative to the level of alkaline phosphatase activity
produced from cotransfected pSVAPAP plasmid (0.5 
 
m
 
g), which con-
tains the reporter gene under the control of the simian virus 40 en-
hancer-promoter (50). Cells were incubated with transfection mix-
tures for 90 min and then were fed M199 medium supplemented with
FBS as indicated. Luciferase and alkaline phosphatase activity
were measured as described previously (51). Results represent the
mean
 
6
 
SEM of three independent transfections.
To study the effect of Ras inactivation on various promoters,
PAC1 cells were cotransfected with the indicated amounts of lu-
ciferase reporter genes and pMT-Ras
 
Asn17
 
 (52) (a gift from G.M. Coo-
per, Dana-Farber Cancer Institute, Boston, MA). Transfection of this
construct results in high levels of basal expression of dominant-nega-
tive human Ras
 
Asn17
 
 mutant driven by the mouse metallothionein-I
gene promoter (52). To rescue the inhibitory effect of Ras
 
Asn17
 
, cells
were cotransfected with pEMSV-c-fos (0.7 
 
m
 
g). Transfected cells
were maintained in 0.5% FBS for 2–3 d and then stimulated with 20%
FBS for 16–18 h.
 
Bromodeoxyuridine (BrdU) incorporation in transfected cell pop-
ulations.
 
PAC1 cells were seeded into 60-mm culture dishes contain-
ing glass coverslips. The next day, cells were cotransfected with
pCMV-CD20 (0.125 
 
m
 
g) (a gift from S. van den Heuvel, Massachu-
setts General Hospital, Boston, MA), pMT-Ras
 
Asn17
 
 (0.5 
 
m
 
g), and
pEMSV-c-fos (1.5 
 
m
 
g) as indicated. Final DNA concentration in
transfection solutions was equalized by adding empty pMT-Bam
expression vector. Cells were maintained in 20% FBS for 36 h and
then were incubated for an additional 13 h in fresh medium contain-
ing 10 
 
m
 
M BrdU (Amersham Corp., Arlington Heights, IL). BrdU
incorporation in transfected cell populations was analyzed by indirect
immunofluorescence using mouse mAbs to the CD20 cell-surface
marker and BrdU. Cells were incubated for 1 h at room temperature
with FITC-conjugated anti-CD20 antibody (1:10 dilution; DAKO
Corp., Carpinteria, CA) and then fixed with 100% methanol. BrdU
immunofluorescent detection was done as described previously (53)
using a biotinylated anti-BrdU antibody (1:60 dilution; Zymed Labo-
ratories, Inc., South San Francisco, CA) and streptavidin-R-phycoery-
thrin (1:400 dilution; Caltag Laboratories, Inc., South San Francisco,
CA). Nuclei were counterstained with 4
 
9
 
, 6-diamidine-2
 
9
 
-phenylin-
dole dihydrochloride (0.5 
 
m
 
g/ml; Boehringer Mannheim Biochemi-
cals, Indianapolis, IN).
 
Electrophoretic mobility shift assay (EMSA).
 
Arterial and PAC1
extracts were prepared as described previously (9). EMSA was car-
ried out in buffer containing 10 mM Tris-HCl (pH 7.5), 4% glycerol,
1 mM MgCl
 
2
 
, 0.5 mM EDTA, 0.5 mM DTT, 50 mM NaCl, and 0.05
mg/ml poly(dI–dC)/poly(dI–dC). After 10 min preincubation on ice,
extracts were incubated for 30 min with a 
 
32
 
P-labeled double-stranded
oligonucleotide probe spanning the human cyclin A promoter region
from 
 
2
 
84 to 
 
2
 
63 (5
 
9
 
-TTGAATGACGTCAAGGCCGCG-3
 
9
 
; CRE
underlined). The mutated CRE oligonucleotide contains the se-
quence from 
 
2
 
84 to 
 
2
 
63 in the 
 
2
 
924/
 
1
 
245 cyclin A CRE mutant re-
porter construct (5
 
9
 
-TTAAATGAATTCAAGGCCGCG-3
 
9
 
) (46).
Unlabeled oligonucleotide was added to the preincubation mixture
for competition assays (25–50-fold molar excess). For supershift ex-
periments, 1 
 
m
 
l of polyclonal antibodies to c-fos (sc-253x) or CRE-
binding protein (CREB)-1 (sc-186x) (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA) was added for an additional 30 min after incubation
with the probe. Binding reactions were separated at 4
 
8
 
C in nondena-
turing 4% acrylamide gels in 0.5
 
3
 
 TBE running buffer (22.5 mM
Tris-borate, 0.5 mM EDTA).
 
Flow cytometry analysis.
 
PAC1 cells were maintained for 3 d in
0.5% FBS/M199 and then stimulated with 20% FBS/M199 for differ-
ent periods of time. Cells were trypsinized, fixed in 100% methanol,
and stained with a solution containing 50 
 
m
 
g/ml each of propidium io-
dide and ribonuclease A (Boehringer Mannheim Biochemicals).
Samples were analyzed in triplicate with a FACScan
 
®
 
 using CellFIT
cell-cycle analysis software (Becton Dickinson, San Jose, CA).
 
Balloon angioplasty, in vivo BrdU labeling, and immunohisto-
chemistry.
 
Balloon denudation of the left common carotid artery in
male Sprague-Dawley rats was performed as described (9, 54). For in
vivo BrdU labeling, rats received two intraperitoneal infusions of
BrdU 24 and 12 h before death (30 mg/kg each dose). Control and
balloon-injured arteries were fixed in situ with 100% methanol, em-
bedded in paraffin, and cut in 5-
 
m
 
m sections. Immunohistochemistry
was done with an mAb to BrdU (1:50 dilution; DAKO Corp.) and a
biotin/streptavidin-peroxidase detection system (Signet Laboratories,
Inc., Dedham, MA). Peroxidase activity was detected with 0.05% (wt/
vol) 3,3
 
9
 
-diaminobenzidine tetrahydrochloride dihydrate substrate
(Vector Laboratories, Inc., Burlingame, CA). For c-fos immunohis-
tochemistry, specimens were treated with antigen retrieval solution
(DAKO Corp.) and biotin/avidin blocking kit (Vector Laboratories,
Inc.) before incubation with a polyclonal antipeptide antibody to
c-fos (sc-052, 1:300 dilution; Santa Cruz Biotechnology Inc.). Peroxi-
dase activity in c-fos–containing immunocomplexes was detected us-
ing AEC substrate (BioGenex Labs, San Ramon, CA).
 
Results
 
Serum stimulation and overexpression of c-fos results in the in-
duction of cyclin A promoter activity dependently of the CRE
and E2F sites in the cyclin A promoter.
 
We showed previously
that VSMC proliferation in response to mechanical acute in-
jury in rat and human arteries correlates with the induction of
CDK2, cyclin E, and cyclin A (43). Since members of the AP-1
family of transcription factors have been implicated in the con-
trol of cellular growth (55), and induction of their expression
precedes the onset of injury-induced VSMC proliferation (56,
57), we explored a potential transcriptional link between the
AP-1 transcription factor c-fos and cyclin A gene expression.
To this end, VSMCs were transiently transfected with lu-
ciferase reporter constructs driven by the human cyclin A pro-
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moter. Cotransfection of c-fos expression vector in serum-
starved VSMCs resulted in a four- to sixfold induction of cyclin
A promoter–dependent reporter activity (Fig. 1 
 
A
 
, constructs
 
A
 
 and 
 
C
 
). Transcription from the cyclin A promoter was also
induced 6–10-fold by serum refeeding of starvation-synchro-
nized VSMCs (Fig. 1 
 
B
 
, constructs 
 
A
 
 and 
 
C
 
; see also Fig. 4, 
 
A
 
and 
 
B
 
), in agreement with previous studies in fibroblasts (45,
47, 58–60). Likewise, serum restimulation induced 6–12-fold
cyclin A promoter activity in transfected 10T1/2 and NIH 3T3
fibroblasts, and c-fos stimulated 4–8-fold cyclin A promoter
activity in serum-starved 10T1/2 cells (data not shown).
Mutations affecting the CRE at position 
 
2
 
79 to 
 
2
 
72 rela-
tive to the major transcription initiation site in the cyclin A
promoter reduced the normal serum-dependent induction of
cyclin A promoter activity (Fig. 1 
 
B
 
, construct 
 
B
 
; see also Fig. 4
 
B
 
), consistent with previous studies in NIH 3T3 fibroblasts
showing that maximal cyclin A promoter activity after serum
restimulation requires the integrity of the CRE (60). As shown
in Fig. 1 
 
A
 
, mutation of the CRE also abrogated c-fos–depen-
dent inducible transcription from the cyclin A promoter in
VSMCs (construct 
 
B
 
). Thus, c-fos overexpression in serum-
starved VSMCs is sufficient to induce cyclin A promoter activ-
ity, and both c-fos– and maximal serum-dependent inducible
transcription from the cyclin A promoter require the integrity
of the CRE at position 
 
2
 
79 to 
 
2
 
72.
Given the pivotal role of E2F transcription factors in G1 to
S phase progression (61–65), we next investigated the role of
E2F on the regulation of cyclin A transcription in VSMCs.
Point mutations that disrupted the E2F motif present at posi-
tion 
 
2
 
37/
 
2
 
32 in the cyclin A promoter abrogated serum-
dependent induction of the 
 
2
 
79/
 
1
 
100 reporter gene in VSMCs
(Fig. 1 
 
B
 
, construct 
 
D
 
), in agreement with previous findings in
NIH 3T3 fibroblasts demonstrating a critical role of this E2F
motif on serum-mediated induction of cyclin A promoter ac-
tivity (47). However, both the basal activity of the 
 
2
 
54/
 
1
 
100
cyclin A promoter region in serum-starved VSMCs and its ac-
tivity in serum-restimulated VSMCs was decreased markedly
(Fig. 1 
 
B
 
, construct 
 
E
 
, and Table I). Thus, the E2F motif at po-
sition 
 
2
 
37/
 
2
 
32 in the human cyclin A gene promoter is neces-
sary but not sufficient for serum-induced activation of cyclin A
transcription.
Notably, c-fos–dependent inducible transcription from the
cyclin A promoter also required the integrity of the 
 
2
 
37/
 
2
 
32
E2F site (Fig. 1 
 
A
 
, construct 
 
D
 
). Moreover, induction of cyclin
A promoter activity by c-fos was blocked by overexpression of
p27
 
Kip1
 
 (Fig. 1 
 
C
 
), an inhibitor of VSMC proliferation (9, 66)
that has been shown to repress cyclin A transcription through
its E2F binding site at 
 
2
 
37 to 
 
2
 
32 (67). Collectively, the re-
sults of these transfection assays indicate that both the CRE at
position 
 
2
 
79/
 
2
 
72 and the E2F motif at position 
 
2
 
37/
 
2
 
32 in
the cyclin A promoter region are required for the normal se-
rum- and c-fos–dependent induction of cyclin A gene expres-
sion.
 
VSMC proliferation induced by serum in vitro and by an-
Figure 1. Both the CRE 
and E2F sites in the cyclin 
A promoter are required 
for c-fos– and serum-
dependent induction of 
cyclin A expression. (A) 
PAC1 cells were tran-
siently transfected with 
luciferase reporter genes 
containing the indicated 
promoter fragments from 
the human cyclin A gene 
(5 mg per transfection). 
2924/1245 CRE mut and 
279/1100 E2F mut refer 
to reporter constructs 
containing point muta-
tions that affected the 
CRE at position 279 to 
272 and the E2F motif at 
position 237 to 232, re-
spectively. Cells were 
maintained in 0.5% FBS 
for 3 d after transfection. 
White bars, Control trans-
fections. Black bars, 
Cells cotransfected with 
pEMSV-c-fos (1 mg). Ac-
tivity of each reporter gene in cells cotransfected with pEMSV-c-fos is normalized relative to its basal activity in the absence of pEMSV-c-fos
(5 1). Except for the 254/1100 construct, activity of cyclin A promoter–dependent reporter genes was nearly identical in serum-starved cells 
(see B and Table I). (B) PAC1 cells transfected as indicated in A were maintained in M199 medium supplemented with 0.5% FBS (white bars) or 
restimulated with 20% FBS (black bars). Activity of each reporter gene is normalized relative to the activity of the 279/1100 construct in se-
rum-starved cells (5 1). (C) PAC1 cells were transfected with 5 mg of 279/1100 cyclin A–luciferase construct and were maintained in M199 
medium supplemented with 0.5% FBS. Cells were cotransfected with 1 mg of c-fos and p27Kip1 expression vectors as indicated. Results are nor-
malized relative to the basal activity in control cells (first bar 5 1).
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gioplasty in vivo is associated with increased binding of c-fos to
the cyclin A CRE. Previous studies have demonstrated the in-
volvement of AP-1/CREB heterodimers in the regulation of
CRE site–dependent transcriptional regulation (55). To test
whether c-fos and CREB-1 factors interact with the cyclin A
CRE, we performed EMSAs using an oligonucleotide probe
bearing this element and extracts prepared at different time
points after serum restimulation of starvation-synchronized
VSMCs. Serum-restimulated cells disclosed a distinct nucleo-
protein complex whose intensity increased transiently during
G1 phase and preceded both the induction of cyclin A pro-
moter activity and DNA synthesis (Fig. 2, A and C). This
nucleoprotein complex required the CRE sequence for its as-
sembly (Fig. 2 A) and contained c-fos and CREB-1 proteins
(Fig. 2 B).
Taken together with the results of our transfection assays,
these findings suggest that binding of c-fos and CREB-1 to the
cyclin A CRE contributes to maximal cyclin A transcription at
G1/S. Evidence that these findings may be relevant in vivo was
provided using the well-characterized rat carotid artery model
of balloon angioplasty, in which increased cyclin A expression
correlates with VSMC proliferation and neointimal accumula-
tion (43). VSMC proliferation after angioplasty in the rat ca-
rotid artery peaks between 33 and 48 h and declines thereafter
to return to baseline levels within 2–3 wk (54, 68). Consistent
with these findings, BrdU incorporation into VSMCs was neg-
ligible in uninjured arteries and 1 d after angioplasty, and in-
creased 3 d after injury (Fig. 3 A). Expression of c-fos was
markedly induced exclusively in VSMCs before the onset of
injury-induced proliferation and coincident with the prolifera-
tive wave (Fig. 3 B). In contrast, c-fos protein was not detected
in uninjured, quiescent arteries, or 18 d after injury, when the
proliferative index has returned to basal levels (Fig. 3 B) (54, 68).
Table I. Reduced Basal Activity and Lack of Serum 
Responsiveness of the 254/1100 Cyclin A Promoter Region in 
Transfected VSMCs
Reporter gene Low serum High serum Ratio low/high
pGL2-Basic 160.1 1.160.1 1
279/1100 cyclin A–Luc 29.662.1 167.1633.6 5.6
254/1100 cyclin A–Luc 2.360.2 1.460.5 0.6
PAC1 cells were cotransfected with the indicated luciferase reporter
genes and pSVAPAP plasmid. Cells were maintained for 2 d in 0.5%
FBS/M199 (Low serum) or serum-restimulated with 20% FBS/M199 af-
ter serum starvation (High serum). Luciferase/alkaline phosphatase ac-
tivity ratios are normalized relative to the activity of the promoterless
pGL2-Basic reporter in serum-starved cells (5 1). Data are expressed as
mean6SEM of three independent transfections.
Figure 2. Serum restimulation of VSMCs induces c-fos and CREB-1 binding to the cyclin A CRE before the stimulation of cyclin A promoter 
activity and DNA synthesis. PAC1 cells were maintained in 0.5% FBS for 3 d and then stimulated with 20% FBS for the indicated periods of 
time. (A) EMSA was performed using a radiolabeled probe containing the cyclin A CRE (284 to 263 cyclin A promoter region). Competition 
experiments were done with a 25-fold excess of 284/263 oligonucleotide. wt, Wild-type. CRE mut, Mutated CRE. Lane P, Binding reaction with 
probe and no extract. (B) Polyclonal antibodies to CREB-1 and c-fos supershifted the nucleoprotein complex in cells stimulated with serum for 
2 h. Arrowheads, The supershifted bands. C, Control unrelated antibody (anti-MEF2). The c-fos and CREB-1 antibodies also gave rise to a su-
pershift in cells stimulated for 8 h (not shown). (C) White bars, Reporter gene activity in cells transfected with the 279/1100 cyclin A–luciferase 
construct (2.5 mg). Results are normalized relative to the activity in serum-starved cells (first bar 5 1). Black bars, Percentage of cells in S and 
G2/M phase was determined by flow cytometry analysis of cells stained with propidium iodide.
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We next examined the binding activity associated with the
cyclin A CRE in response to balloon angioplasty. EMSA dem-
onstrated an injury-induced nucleoprotein complex whose as-
sembly required the cyclin A CRE (Fig. 3, C and D) and
contained c-fos and CREB-1 proteins (Fig. 3 E). This injury-
induced nucleoprotein complex was first detected 8 h after an-
gioplasty, peaked between 3 and 10 d, and then declined (Fig.
3 C). Thus, in agreement with the above findings in cultured
VSMCs, c-fos expression and binding to the cyclin A CRE are
spatially and temporally consistent with a role for this factor in
Figure 3. Expression and 
activity of c-fos after bal-
loon angioplasty in the rat 
carotid artery. BrdU in-
corporation (A) and c-fos 
expression (B) in unin-
jured arteries and at the 
indicated time points af-
ter balloon angioplasty 
were analyzed by immu-
nohistochemistry. Black 
and white arrowheads, 
The internal and external 
elastic lamina, respec-
tively. Arteries were sec-
tioned longitudinally (2- 
and 4-h time points) or 
transversally (rest). Spec-
imens incubated with the 
anti-BrdU antibody were 
counterstained with he-
matoxylin. As negative 
control for BrdU immu-
nostaining, specimens 
were incubated with non-
immune mouse IgG 
(Control IgG). Control 
experiments in which the 
c-fos antibody was prein-
cubated with a 10-fold 
mass excess of immuno-
genic peptide revealed 
no signal (not shown). 
(C–E) EMSA was per-
formed using the cyclin A 
284/263 probe which 
contains the CRE site, 
and arterial extracts pre-
pared at the indicated 
time points after angio-
plasty. Lane U, Unin-
jured. Arrowhead (C) 
The retarded band 
shown in D and E. Com-
petition was done with
5-d postinjury extracts 
and a 50-fold excess of 
the 284/263 cyclin A oli-
gonucleotide. wt, Wild-
type. CRE mt, Mutated 
CRE. Similar results were 
obtained with 3- and 10-d 
postinjury extracts (not 
shown). Supershift assays 
were done using 3-d 
postinjury extract and 
the indicated antibodies. 
Arrowhead, The super-
shifted band.
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injury-induced stimulation of cyclin A expression and VSMC
proliferation in vivo.
Overexpression of c-fos overcomes the inhibitory effect of
Ras inactivation on cyclin A promoter activity and VSMC
proliferation. The Ras proteins are essential for mitogen-stim-
ulated progression through the G1 and S phase of the mam-
malian cell cycle (69–73) and for injury-induced VSMC prolif-
eration in vivo (41, 42). Therefore, we sought to investigate a
potential role for Ras on the regulation of cyclin A gene tran-
scription and VSMC proliferation. As shown in Fig. 4 A, ex-
pression of dominant inhibitory RasAsn17 mutant (52) blocked
the normal induction of c-fos and cyclin A promoter–depen-
dent reporter gene activity in serum-stimulated VSMCs. In
contrast, RasAsn17 did not affect reporter activity driven by the
Rous sarcoma virus (RSV) enhancer-promoter (Fig. 4 A), thus
excluding the possibility that inactivation of Ras might inhibit
essential components of the transcriptional machinery. We
next examined the effect of Ras inactivation on DNA synthe-
sis in VSMCs. To this end, cells were cotransfected with ex-
pression vectors for RasAsn17 and CD20 cell-surface marker.
BrdU incorporation in transfected cell populations was ana-
lyzed by indirect immunofluorescence using antibodies to
CD20 and BrdU. As shown in Fig. 5, RasAsn17 blocked de novo
DNA synthesis in serum-stimulated VSMCs.
The above results link Ras-dependent mitogenic signaling
to inducible c-fos and cyclin A promoter activity and DNA
synthesis in VSMCs, and suggest that inactivation of c-fos may
contribute to the inhibitory effects of RasAsn17. Indeed, overex-
pression of c-fos circumvented efficiently the inhibition of se-
rum-dependent inducible cyclin A promoter activity (Fig. 4 B)
and DNA synthesis (Fig. 5) due to Ras inactivation. As ex-
pected, mutations within the cyclin A CRE that impaired bind-
ing of c-fos abrogated its ability to overcome the inhibitory ef-
fect of RasAsn17 (Fig. 4 B). Together, these findings suggest that
c-fos, through its interaction with the cyclin A CRE, acts in a
signaling cascade that links Ras activity to cyclin A transcrip-
tion and VSMC proliferation.
Discussion
Although several positive and negative regulators of cell cycle
progression have been involved in neointimal lesion develop-
ment after balloon angioplasty (9–27), the molecular mecha-
nisms regulating the expression of cell cycle control genes and
governing VSMC proliferation are poorly understood. In this
study, we investigated the transcriptional regulation of the cy-
clin A gene, a key positive regulator of S phase that is induced
after angioplasty (43). Our results suggest that the interaction
of c-fos/CREB-1 heterodimers with the CRE in the cyclin A
promoter plays an important role in the induction of cyclin A
gene expression and VSMC growth in vitro and in vivo. First,
c-fos overexpression could override the requirement for Ras-
dependent signaling on S phase entry and cyclin A gene tran-
scription in serum-stimulated VSMCs, and this latter effect
required the integrity of the cyclin A CRE site. Second, over-
expression of c-fos in serum-starved VSMCs, which normally
display low cyclin A promoter activity, stimulated transcrip-
tion from the cyclin A promoter in a CRE-dependent manner.
Third, VSMC proliferation induced by both serum in vitro and
balloon angioplasty in vivo was associated with binding of c-fos
and CREB-1 to the cyclin A CRE site. Finally, expression of
c-fos in VSMCs after balloon angioplasty was correlated tem-
porally and spatially with the kinetics of VSMC proliferation.
Previous studies demonstrated the rapid induction of c-myc
and AP-1 factors after balloon angioplasty in the rat aorta,
suggesting that early protooncogene expression contributes to
the initiation of VSMC proliferation in response to acute me-
chanical injury (56, 57). Our EMSA and immunohistochemis-
try analysis in injured arteries extend these previous findings
by demonstrating the sustained DNA-binding activity and ex-
pression of c-fos during the proliferative wave and subsequent
downregulation at later time points coincident with the rees-
tablishment of the quiescent phenotype. Maximal CRE-associ-
ated binding activity preceded the peak of cyclin A promoter–
dependent reporter (luciferase) gene activity in transfected
cells. One potential explanation for this apparent discrepancy
is a delay in translation into luciferase protein after transcrip-
tion of the transfected cyclin A–luciferase reporter and/or the
Figure 4. Overexpression of c-fos circumvents the inhibitory effect of 
Ras inactivation on cyclin A promoter activity. (A) PAC1 cells were 
transfected with luciferase reporter constructs driven by the following 
promoter fragments: cyclin A (279/1100; 2.5 mg), c-fos (2356/1109; 
1 mg), and RSV enhancer-promoter (1 mg). White bars, Control trans-
fections. Black bars, Cells cotransfected with pMT-RasAsn17 (1.5 mg), 
which expresses dominant inhibitory RasAsn17 mutant (52). After 
transfection, cells were maintained for 3 d in 0.5% FBS. Bars show 
the activity of serum-starved cells (0.5% FBS), or cells restimulated 
overnight after serum starvation (20% FBS). Activity in control se-
rum-stimulated cells is defined as 100%. (B) PAC1 cells were trans-
fected with 2.5 mg of 2924/1245 cyclin A–luciferase construct. wt, 
Wild-type. CRE mut, Mutated CRE. White bars, Control transfec-
tions. Black bars, Cells cotransfected with pMT-RasAsn17 (0.25 mg). 1, 
Cotransfection of pEMSV-c-fos expression vector (c-fos; 0.7 mg). 
Transfected cells were serum-starved for 2 d and then stimulated 
overnight with 20% FBS. Activity of each reporter construct is nor-
malized relative to basal activity in serum-starved cells (first bar 5 1).
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requirement of additional factors at later time points after se-
rum restimulation (see below).
It has been shown previously that the E2F motif at position
 
2
 
37/
 
2
 
32 in the cyclin A promoter region is necessary for se-
rum responsiveness of cyclin A expression in NIH 3T3 fibro-
blasts (47). While our results with the 
 
2
 
79/
 
1
 
100 E2F mutant
in transfected VSMCs are consistent with this notion, the re-
sults with the 
 
2
 
54/
 
1
 
100 reporter indicate that the E2F site at
position 
 
2
 
37/
 
2
 
32 is not sufficient to confer the normal serum-
dependent induction of cyclin A promoter activity. Likewise,
the CRE site at position 
 
2
 
79/
 
2
 
72 appears to be necessary for
maximal cyclin A promoter activity in serum-stimulated NIH
3T3 cells (60) and VSMCs (Fig. 1 
 
B
 
 and Fig. 4 
 
B
 
). Collectively,
these results suggest that both the 
 
2
 
79/
 
2
 
72 CRE and the 
 
2
 
37/
 
2
 
32 E2F sites in the cyclin A promoter region are required for
the normal serum-dependent induction of cyclin A expression.
Further evidence supporting this notion was provided by ana-
lyzing the role of E2F on c-fos–dependent induction of cyclin
A transcription. Indeed, the ability of c-fos to stimulate cyclin
A promoter activity in transfected VSMCs was abrogated
when E2F function was disrupted either by point mutations of
its binding site in the cyclin A promoter or by overexpression
of p27
 
Kip1
 
, an inhibitor of VSMC proliferation (9, 66) that re-
presses cyclin A promoter activity through its E2F motif (67).
While Ras-dependent signaling is essential for injury-
induced VSMC proliferation in vivo (41, 42) and growth fac-
tor–dependent activation of the G1 CDK/cyclin/E2F pathway
in vitro (34–40), the molecular basis of these events is not well
understood. Previous studies in fibroblasts have implicated
Ras-dependent signaling and c-jun in the activation of the cy-
clin D1 promoter (74–76), a key regulator of G1 phase. Our re-
sults demonstrate that Ras activity is essential for the normal
induction of c-fos and cyclin A promoter activity, as well as
DNA replication in serum-stimulated VSMCs. Ectopically ex-
pressed c-fos, through its interaction with the CRE, circum-
vented the inhibitory effect of Ras inactivation on cyclin A
promoter activity and was effective at restoring mitogen-
induced DNA synthesis in the absence of Ras activity. Thus,
the AP-1 transcription factors appear to play an important role
in linking the Ras and cell cycle regulatory pathways in differ-
ent cell types. Of note, repression of cyclin A promoter activity
by Ras
 
Asn17
 
 in the presence of serum was approximately four-
Figure 5. Overexpres-
sion of c-fos overcomes 
the inhibitory effect of 
Ras inactivation on DNA 
synthesis. PAC1 cells 
were cotransfected with 
pMT-RasAsn17 (0.5 mg) 
and pCMV-CD20 (0.125 
mg) expression vectors. 
To rescue the inhibitory 
effect of RasAsn17, cells 
were cotransfected with 
pEMSV-c-fos (c-fos; 1.5 
mg). Cells were main-
tained in 20% FBS and 
labeled with BrdU for in-
direct immunofluores-
cence analysis. Incor-
poration of BrdU in 
transfected cell popula-
tions was analyzed using 
FITC-conjugated anti-
CD20 antibody (green) 
and biotin-conjugated 
anti-BrdU antibody. 
BrdU-containing immu-
nocomplexes were de-
tected using streptavidin-
R-phycoerythrin (red). 49, 
6-diamidine-29-phenylin-
dole dihydrochloride nu-
clear counterstaining of 
each field is also shown 
(blue). Black and white 
arrowheads, CD20-posi-
tive/BrdU-negative and 
CD20-positive/BrdU-pos-
itive cells, respectively. 
(Bottom) Approximately 
250 CD20-positive cells 
were scored in each ex-
periment.
 
c-fos– and E2F-dependent Control of Cyclin A Transcription in Vascular SMCs 947
fold for either the wild-type or the CRE mutant reporter con-
structs. When taken together with recent studies demonstrat-
ing that Ras inactivation blocks the normal serum-dependent
accumulation of E2F and prevents the induction of cyclin A
mRNA levels (36), these results suggest that suppression of
E2F function may contribute to the inhibitory effect of
RasAsn17 on the CRE mutant construct.
On the basis of our results and recent studies (34–40, 74–
76), it is clear that the molecular mechanisms coupling Ras-
mediated signaling to the cell cycle machinery are complex.
We propose that c-fos and E2F transcription factors are down-
stream effectors of Ras which stimulate cyclin A gene expres-
sion and VSMC proliferation. When taken together with our
in vivo data demonstrating the localized expression of c-fos in
VSMCs and its interaction with the cyclin A CRE in response
to balloon denudation, these findings illustrate a new tran-
scriptional network that may be relevant to the development
of vascular proliferative lesions.
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